Ruby Srivastava
Indian Institute of Technology Bombay, Centre for Cellular and Molecular Biology, University of Lucknow, CSIR-IICT
0000-0002-2367-0176
About
Dr. Ruby Srivastava is a Principal Investigator at Indian Institute of Technology Bombay, Mumbai, India. She is working on "Reverse Vaccinology for design and development of mRNA Vaccines" under DST/WIDUSHI-B/CS/2024/35 Scheme. Before that she worked on "Theoretical studies on unfolding the mystery of RNA: As an application towards biomedical and green electronics" at the Centre for Cellular and Molecular Biology-CSIR, Hyderabad. In addition to solo authoring a number of articles and 16 solo book chapters, she has served as the editor of a number of books, with 2 solo authored books. Her expertise includes computational studies on material sciences and biological sciences, while her current research interests include Artificial Intelligence in Multiomics studies, drug discovery, drug repurposing, Target protein degradation, Quantum Information Science in Drug Discovery and Immunoinformatics studies of mRNA vaccines for viral and bacterial infections and cancers.
Employment
-
Indian Institute of Technology Bombay Principal Investigator2025 - Present
-
Centre for Cellular and Molecular Biology Principal Investigator2019 - 2024
-
CSIR-IICT Principal Investigator2015 - 2018
-
CSIR-IICT Principal Investigator2011 - 2014
Education
-
University of Lucknow PhD2005 - 2010
Projects & Funding
Projects & funding information is unavailable.
Publications (28)
- An immunoinformatics approach to study the physicochemical properties and efficacy of mRNA-1273 against SARS-CoV-2 Save
- Integrative bioinformatics analysis of APOE variants in Alzheimer’s disease and clinical therapeutics Save
- Artificial intelligence meets epigenetics: a new frontier in precision oncology Save
- CircRNA-miRNA-mRNA interactome analysis to explore potential pathogenesis of ovarian cancer Save
- Stimuli-responsive nanomaterials for the precision delivery of mRNA cancer vaccines Save
- 159Chapter 7 Predicting polymer properties: machine learning insights from Polymer GenomePolymer Genome Save
- Biological Efficacy of 40 Noncovalent SARS-CoV-2 Main Protease Inhibitors: A Computational Study Save
- Theoretical studies on safety and efficacy of 16 small-molecule MC4R antagonists as therapeutics for obesity Save
- Sustainable Green Biomaterials in Drug Delivery Save
- Physicochemical properties and biological efficacy of 30 DYRK2 Inhibitors for the treatment of prostate cancer Save